---
title: "礼来公司的奥莫沃显示，可使溃疡性结肠炎患者的排便急迫症状早期得到改善且效果持久。"
description: "礼来公司的奥莫沃显示，可使溃疡性结肠炎患者的排便急迫症状早期得到改善且效果持久。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/262872628.md"
published_at: "2025-10-27T10:46:01.000Z"
---

# 礼来公司的奥莫沃显示，可使溃疡性结肠炎患者的排便急迫症状早期得到改善且效果持久。

礼来公司的奥莫沃显示，可使溃疡性结肠炎患者的排便急迫症状早期得到改善且效果持久。

### Related Stocks

- [LLY.US - 礼来](https://longbridge.com/zh-CN/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly and Company $LLY Shares Acquired by Assetmark Inc. | Assetmark Inc. increased its holdings in Eli Lilly and Company (NYSE: LLY) by 6.0% in Q3, owning 55,360 shares valued at | [Link](https://longbridge.com/zh-CN/news/275971336.md) |
| Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill | Eli Lilly (LLY) has prepared a $1.5 billion inventory of its new weight-loss pill, Orforglipron, ahead of its anticipate | [Link](https://longbridge.com/zh-CN/news/276070062.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/zh-CN/news/275551012.md) |
| Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients | Eli Lilly's Phase 3 LIBRETTO-432 trial for Retevmo (selpercatinib) shows significant reduction in recurrence risk for ea | [Link](https://longbridge.com/zh-CN/news/276119494.md) |
| US issues travel advisory for these islands amid virus outbreak | The CDC has issued a "Level 2" travel advisory for the Seychelles due to a chikungunya virus outbreak. Travelers are urg | [Link](https://longbridge.com/zh-CN/news/275778861.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
